b'Scientific Session Abstracts SATURDAY APRIL 20, 2024 NegativeStressPositive Stress TestTestP Valuen = 5,752 n = 1,398Anesthesia 0.94Local/Regional 5710 (99.3%) 1387 (99.3%)General 40 (0.7%) 10 (0.7%)Presentation 0.049Asymptomatic 4206 (79.8%) 1051 (81.9%)Symptomatic 987 (18.7%) 207 (16.1%)Rupture 80 (1.5%) 26 (2.0%)Severe Leg Dysfunction or28 (0.5%) 4 (0.3%) 0.32ParalysisPreop ASA 3532 (61.4%) 1036 (74.1%) 0.001Preop P2Y12 Antagonist 681 (11.9%) 284 (20.4%) 0.001Preop Statin 4078 (70.9%) 1132 (81.0%) 0.001Preop Beta Blocker 3861 (67.1%) 1092 (78.2%) 0.001Preop Ace Inhibitor 2642 (46.5%) 728 (52.6%) 0.001Preop Anticoagulation 823 (14.5%) 243 (17.6%) 0.004Urgency 0.17Elective 5222 (90.9%) 1286 (92.1%)Urgent or Emergent 523 (9.1%) 111 (7.9%)Pathology 0.001Aneurysm 4537 (78.9%) 1182 (84.5%)Dissection 647 (11.2%) 96 (6.9%)Other 568 (9.9%) 120 (8.6%)Table II. Postoperative outcomes of stroke, myocardial infarction, / spinal cord ischemia and 30- day mortality in TEVAR patients,stratified by preoperative cardiac stress testing resultPositive Preoperative Stress Test vs Negative Preoperative Stress TestaOR (95% CI) Outcome (Reference = NegativeP valueStress Test)Stroke 1.48 (1.02-2.16) 0.039MI 2.06 (1.59-2.67) 0.001SCI 1.07 (0.68-1.66) 0.77830-day mortality 1.44 (1.08-1.91) 0.012aOR, adjusted odds ratio; CI, confidence interval; AI, myocardial infarction; SCI, spinal cord ischemia50SOUTHERN CALIFORNIA VASCULAR SURGICAL SOCIETY'